Oramed Pharmaceuticals (NASDAQ:ORMP) versus Pharming Group (NASDAQ:PHAR) Financial Analysis

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) and Pharming Group (NASDAQ:PHAR – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Earnings and Valuation

This table compares Oramed Pharmaceuticals and Pharming Group”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oramed Pharmaceuticals $2.00 million 80.24 $64.05 million $6.16 0.60
Pharming Group $376.13 million 2.33 $2.85 million $0.32 38.69

Oramed Pharmaceuticals has higher earnings, but lower revenue than Pharming Group. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Oramed Pharmaceuticals and Pharming Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oramed Pharmaceuticals N/A -6.97% -6.01%
Pharming Group 6.23% 8.70% 4.93%

Institutional and Insider Ownership

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 20.8% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Oramed Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Oramed Pharmaceuticals and Pharming Group, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oramed Pharmaceuticals 0 0 1 0 3.00
Pharming Group 0 2 3 0 2.60

Pharming Group has a consensus price target of $39.67, indicating a potential upside of 220.41%. Given Pharming Group’s higher possible upside, analysts plainly believe Pharming Group is more favorable than Oramed Pharmaceuticals.

About Oramed Pharmaceuticals

(Get Free Report)

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral drug-delivery technologies. Its platform is designed to protect protein-based medicines as they pass through the digestive system and support their absorption, with the aim of delivering medicines by mouth that have traditionally been given by injection. The company’s research has focused on oral treatments for metabolic conditions, including ORMD-0801, an oral insulin candidate, and an oral GLP-1 candidate. These products are investigational; Oramed does not market them as approved treatments.

About Pharming Group

(Get Free Report)

Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.